These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28603949)

  • 1. Science-in-brief: Bisphosphonate use in the racehorse: Safe or unsafe?
    McLellan J
    Equine Vet J; 2017 Jul; 49(4):404-407. PubMed ID: 28603949
    [No Abstract]   [Full Text] [Related]  

  • 2. Tiludronate and clodronate do not affect bone structure or remodeling kinetics over a 60 day randomized trial.
    Richbourg HA; Mitchell CF; Gillett AN; McNulty MA
    BMC Vet Res; 2018 Mar; 14(1):105. PubMed ID: 29554967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis].
    Tanaka M; Mori H; Shimizu K; Toshiyuki ; Matsuoka ; Yamamotoya H; Minamide T; Mori M; Nozaki K; Usui T; Shimokawa K; Suzuki H; Aoyama K; Kimoto A; Sasamata M; Miyata K
    Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):149-57. PubMed ID: 19749488
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of bone resorption blunts osteoarthritis in mice with high bone remodelling.
    Kadri A; Funck-Brentano T; Lin H; Ea HK; Hannouche D; Marty C; Lioté F; Geoffroy V; Cohen-Solal ME
    Ann Rheum Dis; 2010 Aug; 69(8):1533-8. PubMed ID: 20525838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of the Mechanism of Action and Use of Bisphosphonates in Horses.
    Yocom A; Contino E; Kawcak C
    J Equine Vet Sci; 2023 Aug; 127():104503. PubMed ID: 37120118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical implications of bisphosphonate for bone metastases of prostate cancer].
    Kitagawa Y; Konaka H; Mizokami A; Namiki M
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():356-9. PubMed ID: 18161131
    [No Abstract]   [Full Text] [Related]  

  • 7. [When should bisphosphonate treatment be discontinued?].
    Eriksen EF; Halse J
    Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1630-2. PubMed ID: 22875131
    [No Abstract]   [Full Text] [Related]  

  • 8. [Bone Cell Biology Assessed by Microscopic Approach. The effects of bisphosphonates on bone remodeling, microdamage accumulation and fracture repair process].
    Mashiba T
    Clin Calcium; 2015 Oct; 25(10):1537-40. PubMed ID: 26412734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do not use bisphosphonates without scientific evidence, neither in treatment nor prophylactic, in the treatment of stress fractures.
    Ekenman I
    Knee Surg Sports Traumatol Arthrosc; 2009 May; 17(5):433-4. PubMed ID: 19238357
    [No Abstract]   [Full Text] [Related]  

  • 10. Tiludronate infusion in the treatment of bone spavin: a double blind placebo-controlled trial.
    Gough MR; Thibaud D; Smith RK
    Equine Vet J; 2010 Jul; 42(5):381-7. PubMed ID: 20636772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonate treatment delays stress fracture remodeling in the rat ulna.
    Kidd LJ; Cowling NR; Wu AC; Kelly WL; Forwood MR
    J Orthop Res; 2011 Dec; 29(12):1827-33. PubMed ID: 21598308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biphosphonate in the treatment of avascular necrosis of the femoral head].
    Shabtai L; Drexler M; Blummberg N
    Harefuah; 2012 Apr; 151(4):242-5, 252. PubMed ID: 22616155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates and bone diseases: past, present and future.
    Heymann D
    Curr Pharm Des; 2010; 16(27):2948-9. PubMed ID: 20722613
    [No Abstract]   [Full Text] [Related]  

  • 14. Osteoarthritis: Osteoporotic OA: a reasonable target for bone-acting agents.
    Herrero-Beaumont G; Roman-Blas JA
    Nat Rev Rheumatol; 2013 Aug; 9(8):448-50. PubMed ID: 23857129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of tiludronate in the treatment of horses with signs of pain associated with osteoarthritic lesions of the thoracolumbar vertebral column.
    Coudry V; Thibaud D; Riccio B; Audigié F; Didierlaurent D; Denoix JM
    Am J Vet Res; 2007 Mar; 68(3):329-37. PubMed ID: 17331024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates: how do they work?
    Papapoulos SE
    Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):831-47. PubMed ID: 19028359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates and the dental patient: part 1.
    Zak M; Spina AM; Spinazze RP; Perkinson WL; Spinazze DJ
    Compend Contin Educ Dent; 2007 Aug; 28(8):464-8; quiz 469-70. PubMed ID: 18578104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of antiresorptive therapy on the structural and material properties of bone strength].
    Kishimoto H
    Clin Calcium; 2016 Jan; 26(1):107-15. PubMed ID: 26728537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Determinants of bone quality and strength independent of bone remodeling].
    Saito M; Marumo K
    Clin Calcium; 2016 Jan; 26(1):29-41. PubMed ID: 26728528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic implications of suppressing osteoclast formation versus function.
    Teitelbaum SL
    Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii61-ii63. PubMed ID: 27856662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.